Literatur
- 1
Ahmad A M, Guzder R, Wallace A M. et al .
Circadian and ultradian rhythm and leptin pulsatility in adult GH deficiency: effects
of GH replacement.
J Clin Endocrinol Metab.
2001;
86
3499-3506
- 2
Baum H B, Biller B M, Finkelstein J S. et al .
Effects of physiologic growth hormone therapy on bone density and body composition
in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled
trial.
Ann Intern Med.
1996;
125
883-890
- 3
Baum H B, Katznelson L, Sherman J C. et al .
Effects of physiological growth hormone (GH) therapy on cognition and quality of life
in patients with adult-onset GH deficiency.
J Clin Endocrinol Metab.
1998;
83
3184-3189
- 4
Bell W, Davies J S, Evans W D. et al .
Somatic characteristics and cardiovascular risk factors in growth hormone deficiency:
A randomized, double-blind, placebo-controlled study of the effect of treatment with
recombinant human growth hormone.
Am J Hum Biol.
2004;
16
533-543
- 5
Bengtsson B A, Eden S, Lonn L. et al .
Treatment of adults with growth hormone (GH) deficieny with recombinant human GH.
J Clin Endocrinol Metab.
1993;
76
309-317
- 6
Beshyah S A, Shahi M, Skinner E. et al .
Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults.
Eur J Endocrinol.
1994;
130
451-458
- 7
Bex M, Abs R, Maiter D. et al .
The effects of growth hormone replacement therapy on bone metabolism in adult-onset
growth hormone deficiency: a 2-year open randomized controlled multicenter trial.
J Bone Miner Res.
2002;
17
1081-1094
- 8
Biller B M, Sesmilo G, Baum H B. et al .
Withdrawal of long-term physiological growth hormone (GH) administration: differential
effects on bone density and body composition in men with adult-onset GH deficiency.
J Clin Endocrinol Metab.
2000;
85
970-976
- 9
Bryant J.
The clinical effectiveness and cost effectiveness of the use of human growth hormone
in adults.
Health Technol Assess.
2002;
6
1-106
- 10
Bulow B, Ahren B, Erfurth E M.
Increased leptin and tumor necrosis factor ( per unit fat mass in hypopituitary women
without growth hormone treatment.
Eur J Endocrinol.
2001;
146
737-742
- 11
Burman P, Broman J E, Hetta J. et al .
Quality of life in adults with growth hormone (GH) deficiency: response to treatment
with recombinant human GH in a placebo-controlled 21-month trial.
J Endocrinol Metab.
1995;
80
3585-3590
- 12
Caidahl K, Eden S, Bengtsson B A.
Cardiovascular and renal effects of growth hormone.
Clin Endocrinol (Oxf).
1994;
40
393-400
- 13
Carroll P V, Drake W M, Maher K T. et al .
Comparison of continuation or cessation of growth hormone (GH) therapy on body composition
and metabolic status in adolescents with severe GH deficiency at completion of linear
growth.
J Clin Endocrinol Metab.
2004;
89
3890-3895
- 14
Chihara K, Koledova E, Shimatsu A. et al .
Adult GH deficiency in japanese patients: effects of GH treatment in a randomised,
placebo-controlled trial.
Eur J Endocrinol.
2004;
151
343-350
- 15
Colao A, di Somma C, Cuocolo A. et al .
Improved cardiovascular risk factors and cardiac performance after 12 months of growth
hormone (GH) replacement in young adult patients with GH deficiency.
J Clin Endocrinol Metab.
2001;
86
1874-1881
- 16
Davidson P, Milne R, Chase D. et al .
Growth hormone replacement in adults and bone mineral density: a systematic review
and meta-analysis.
Clin Endocrinol.
2004;
60
92-98
- 17
Degerblad M, Almkvist O, Grunditz R. et al .
Physical and psychological capabilities during substitution therapy with recombinat
growth hormone in adults with growth hormone deficiency.
Acta Endocrinol.
1990;
123
185-193
- 18
Deijen J B, de Boer H, Blok G J. et al .
Cognitive impairments and mood disturbances in growth hormone deficient men.
Psychoneuroendocrinology.
1996;
21
313-322
- 19
De Novaes Soares C, Musolino N R, Neto M C. et al .
Impact of recombinat human growth hormone (RH-GH) treatment on psychatric, neuropsychological
and clinical profiles of GH deficient adults.
Arq Neuropsiquiatr.
1999;
57
182-189
- 20
Elhadd T A, Abdu T A, Oxtoby J. et al .
Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism
and severe GH deficiency.
J Clin Endocrinol Metab.
2001;
86
4223-4232
- 21
Ezzat S, Fear S, Gaillard R C. et al .
Gender-specific responses of lean body composition and non-gender-specific cardiac
function improvement after GH replacement in GH-deficient adults.
Horm Res.
2002;
11
273-281
- 22
Fernholm R, Bramnert M, Hagg E. et al .
Growth hormone replacement therapy improves body composition and increases bone metabolism
in elderly patients with pituitary disease.
J Clin Endocrinol Metab.
2000;
85
4104-4112
- 23
Finkenstedt G, Gasser R W, Hofle G. et al .
Effects of growth hormone (GH) replacement on bone metabolism and mineral density
in adult onset of GH deficiency: results of a double-blind placebo-controlled study
with open follow-up.
Eur J Endocrinol.
1997;
136
282-289
- 24
Florkowski C M, Stevens S, Joyce P. et al .
Growth hormone replacement does not improve psychlogical well being in adult hypopituitarism:
a randomised cross over trial.
Psychoneuroendocrinology.
1998;
23
57-63
- 25
Fort S, Weaver J, Monson J. et al .
The effects of low-dose recombinant human growth hormone on cardiovascular structure
and function in hypopituitarism growth hormone-deficient adults.
Endocrinol Metab.
1995;
2
119-126
- 26
Gillberg P, Bramnert M, Thoren M. et al .
Commencing growth hormone replacement in adults with a fixed low dose: effects on
serum lipoproteins, glucose metabolism, body composition and cardiovascular function.
Growth Hormon IGF Res.
2001;
11
273-281
- 27
Giusti M, Meineri I, Malagamba D. et al .
Impact of recombinant human growth hormone treatment on psychological profiles in
hypopituitary patients with adult-onset growth hormone deficiency.
Eur J Clin Invest.
1998;
28
13-19
- 28
Gotherstrom G, Svensson J, Koranyi J. et al .
A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained
effects on body composition, bone mass and metabolic indices.
J Clin Endocrinol Metab.
2001;
86
4657-4665
- 29
Hansen T B, Brixen K, Vahl N. et al .
Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium
homeostasis, and bone metabolism in adults with aquired GH deficiency: a double blind,
randomized, placebo-controlled study.
J Clin Endocrinol Metab.
1996;
81
3352-3359
- 30
Herschbach P, Henrich G, Strasburger C J. et al .
Development and psychometric properties of a disease-specific quality of life questionnaire
for adult patients with growth hormone deficiency.
Eur J endocrinol.
2001;
145
255-265
- 31
Hull K L, Harvey S.
Growth hormone therapy and qualitiy of life: possibilities, pitfalls and mechanisms.
J Endocrinol.
2003;
179
311-333
- 32
Jadad A R, Moore R A, Carroll D. et al .
Assessing the quality of reports of randomized clinical trials: blinding necessary?.
Control Clin Trials.
1996;
17
1-12
- 33
Kann P, Piepkorn B, Schehler B. et al .
Effect of long-term treatment with GH on bone metabolism, bone mineral density and
bone elasticity in GH-deficient adults.
Clin Endocrinol (Oxf).
1998;
48
561-568
- 34
Kearney T, Navas de Gallegos C, Chrisoulidou A. et al .
Hypopituitarism is associated with triglyceride enrichment of very low-density lipoprotein.
J Clin Endocrinol Metab.
2001;
86
3900-3906
- 35
Kreitschmann-Andermahr I, Hoff C, Saller B. et al .
Prevalence of pituitary deficiency in patients after aneurysmal subarachnoid hemorrhage.
J Clin Endocrinol Metab.
2004;
89
4986-4992
- 36
Lehnert H.
Hormones and metabolism - exciting paths from biology to clinics.
Dtsch Med Wochenschr.
2005;
130
1573-1576
- 37
Link K, Bulow B, Westman K. et al .
Low individualized growth hormone (GH) dose increased renal and cardiac growth in
young adults with childhood onset GH deficiency.
Clin Endocrinol (Oxf).
2001;
55
741-748
- 38
Mahajan T, Crown A, Checkley S. et al .
Atypical depression in growth hormone deficient adults, and the beneficial effects
of growth hormone treatment on depression and quality of life.
Eur J Endocrinol.
2004;
151
325-332
- 39
Maison P, Chanson P.
Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis.
Circulation.
2003;
108
2648-2652
- 40
Marzullo P, Buckway C, Pratt K L. et al .
Leptin concentrations in GH deficiency: The effect of GH insensitivity.
J Clin endocrinol Metab.
2002;
87
540-545
- 41
McGauley G A.
Qualtiy of life assessment before and after growth hormone treatment in adults with
growth hormone deficiency.
Acta Paediatr Scand Suppl.
1989;
356
70-72; discussion: 73 - 74
- 42
Nass R, Huber R M, Klauss V. et al .
Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac
and pulmonary function in patients with GH deficiency aquired in adulthood.
J Clin Endocrinol Metab.
1995;
80
552-557
- 43
Nielsen S, Moller N, Christiansen J S. et al .
Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Diabetes.
2001;
50
2301-2308
- 44
Randeva H S, Murray R D, Lewandowski K C. et al .
Differential effects of GH replacement on the components of the leptin system in GH-deficient
individuals.
J Clin endocrinol Metab.
2002;
87
798-804
- 45
Renehan A G, Zwahlen M, Minder C. et al .
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic
review and meta-regression analysis.
Lancet.
2004;
363
1346-1353
- 46
Sackett D L, Rosenberg W M, Gray J A. et al .
Evidence based medicine: what it is and what it isnŽt.
BMJ.
1996;
312
71-72
- 47
Schneider H J, Schneider M, von Rosen F. et al .
Hypophyseninsuffizienz nach Schädel-Hirn-Trauma.
Dtsch Arztebl.
2004;
101
A 712-717
- 48
Smit J WA, Janssen Y JH, Lamb H J. et al .
Six months of recombinant human GH therapy in patients with ischemic heart failure
does not influence left ventricular function and mass.
J Clin endocrinol Metab.
2001;
86
4638-4643
- 49
Sneppen S, Steensgaard-Hansen F, Feldt-Rasmussen U.
Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient
adults.
Horm Res.
2002;
58
21-28
- 50 Society for Endocrinology .The use of growth hormone replacement in adult patients
with severe growth hormone deficiency. A position statement. Bristol, UK: Society
for Endocrinology 2000
- 51 Society for Endocrinology .Topical briefings: adult growth hormone replacement. Bristol,
UK: Society for Endocrinology 2001
- 52
Svensson J, Bengtsson B A, RosenT. et al .
Malignant disease and cardiovascular morbidity in hypopituitary adults with or without
growth hormone therapy.
J Clin Endocrinol Metab.
2004;
89
3309-3312
- 53
Takala J, Ruokonen E, Webster N R. et al .
Increased mortality associated with growth hormone treatment in critically ill adults.
N Engl J Med.
1999;
341
785-792
- 54
Thorner M O.
Critical evaluation of the safety of recombinant human growth hormone administration:
Statement from the Growth Hormone Research Society.
J Clin Endocrinol Metab.
2001;
86
1868-1870
- 55
Thuesen L, Jorgensen J O, Muller J R. et al .
Short and long-term cardiovascular effects of growth hormone therapy in growth hormonedeficient
adults.
Clin Endocrinol (Oxf).
1994;
41
615-620
- 56
Valcavi R, Gaddi O, Zini M. et al .
Cardiac performance and mass in adults with hypopituitarism: effects of one year of
growth hormone treatment.
J Clin Endocrinol Metab.
1995;
80
659-666
- 57
Van der Lely A J.
Justified and unjustified use of growth hormone.
Postgrad Med J.
2004;
80
577-580
- 58
Wallymahmed M E, Foy P, Shaw D. et al .
Quality of life, body composition and muscle strength in adult growth hormone deficiency:
the influence of growth hormone replacement therapy for up to 3 years.
Clin Endocrinol (Oxf).
1997;
47
439-446
- 59
Weaver J U, Monson J P, Noonan K. et al .
The effect of low dose recombinant human growth hormone replacement on indices of
bone remodelling and bone mineral density in hypopituitary growth hormone-deficient
adults.
Endocrinol Metab.
1996;
3
(Suppl)
55-61
- 60
Wilhelm B, Kann P.
Einfluss einer 7-jährigen Wachstumshormonsubstitution auf Knochenstoffwechsel, Knochendichte
und Knochenqualität bei Erwachsenen mit einem Wachstumshormonmangel.
Med Klin.
2004;
99
569-577
9 (KIMS-Board: Unabhängiger wissenschaftlicher Beirat von KIMS (Pfizer International
Metabolic Study). Auswertung und wissenschaftliche Aufarbeitung der im Zusammenhang
mit der vom BfArM angeordneten Anwendungsbeobachtung generierten Daten in Deutschland.)
Priv.-Doz. Dr. med. Walter Josef Faßbender
Hospital zum Hl. Geist Kempen, Abteilung für Innere Medizin, Akademisches Lehrkrankenhaus
der Universität Düsseldorf
Von Broichhausen-Allee 1
47906 Kempen/Ndrh.
Phone: 02152/142381
Fax: 02152/142311
Email: w.j.fassbender@krankenhaus-kempen.de
